Phase 4 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are scheduled to have a planned (non-emergency) lung surgery using a minimally invasive technique called VATS lobectomy, where a section of the lung is removed.
- People who have been diagnosed with early-stage non-small cell lung cancer (a common type of lung cancer), up to a certain stage of disease spread (confirm with trial site for exact staging details).
Who may not be able to join:
- People whose immune system is weakened, due to illness or medication.
- People who have had previous surgery on their lungs.
- People who are taking steroid medications (such as cortisone or prednisone) or drugs that suppress the immune system before the surgery.
- People whose diabetes is not well controlled.
- People with significant heart failure (classified as a more severe level of heart failure, confirm with trial site).
- People who have an active infection before surgery, as shown by certain blood test results being above a set level.
- People who have low red blood cell levels (anaemia) before surgery, as shown by a blood test result below a certain level.
- People who have a long-term (chronic) inflammatory condition.
- People who have inflammatory bowel disease (such as Crohn's disease or ulcerative colitis).
- People assigned to one specific treatment group in this trial may not be able to join if they receive opioid pain relief medications at any point during the study period.
- People assigned to the other specific treatment group in this trial may not be able to join if they receive certain other medications during the study period, including dexmedetomidine, lidocaine infusion, ketamine, gabapentinoid drugs, or steroid medications (confirm with trial site for details on which group this applies to).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Vasileia Nyktari, MD, PhD, University of Crete, Medical school
Phone: 00306978702023
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Neutrophil to Lymphocyte ratio (NLR); Platelet to Lymphocyte ratio (PLR); Lymphocyte to monocyte ratio (LMR); Advanced Lung Cancer Inflammation Index (ALI); Systemic Immune Inflammation Index (SII); Prognostic Nutritional Index (PNI); Surgical Stress Response - IL-6 - preoperatively; Surgical Stress Response - IL-6 - end of surgery; Surgical Stress Response - IL-6 - 24 hours after the end of surgery; Surgical Stress Response - IL-8 - preoperatively; Surgical Stress Response - IL-8 - end of surgery; Surgical Stress Response - IL-8 - 24 hours after the end of surgery; Surgical Stress Response -...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.